<DOC>
	<DOCNO>NCT00010166</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Gemcitabine may make tumor cell sensitive radiation therapy . Combining chemotherapy radiation therapy surgery may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine radiation therapy treat patient undergone surgery remove cancer pancreas .</brief_summary>
	<brief_title>Gemcitabine Radiation Therapy Treating Patients With Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : - Determine time disease progression , local control , survival patient previously resect pancreatic cancer treat adjuvant gemcitabine radiotherapy . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30-60 minute day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 , 29 , 32 undergo radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-38 absence disease progression unacceptable toxicity . Beginning least 4 week chemoradiotherapy , patient without disease progression le 10 % weight loss study receive additional gemcitabine IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day total 2 course . Patients follow every 8 week 6 month every 3 month 2 year . PROJECTED ACCRUAL : A total 72 patient accrue study within 2.2 3.4 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive adenocarcinoma pancreas Prior gross total resection via pancreaticoduodenectomy ( Whipple resection total pancreatectomy ) within past 2 month No clinical evidence gross residual disease time surgery No focally positive margin ( tumor margin ) No unresected nodal disease metastatic disease liver , peritoneal surface , elsewhere PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : More 6 month Hematopoietic : Granulocyte count great 1,500/mm3 Hemoglobin great 10 g/dL Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.0 mg/dL Other : Able maintain adequate oral nutrition Documented stable weight ( 5 lb weight loss ) least 2 week prior study No malignancy within past 2 year except inactive nonmelanoma skin cancer carcinoma situ cervix breast Nonmetastatic prostate cancer allow 2 year survival likely No serious medical psychiatric illness would preclude study limit survival le 2 year Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent routine growth factor Chemotherapy : No prior chemotherapy pancreatic cancer Endocrine therapy : Not specify Radiotherapy : No prior abdominal radiotherapy pancreatic cancer Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>